Table 3.
Effect of KV7-inhibitors/openers on 3,4-DAP-induced salivation.
| Groups | Saliva volume (μl) | |
|---|---|---|
| WKY | SHR | |
| PBS+3,4-DAP (control) | 394±96 | 131±52* |
| Hexamethonium+3,4-DAP | 34±2† | |
| Reserpine+PBS+3,4-DAP | 25±11† | |
| Methoctramine+PBS+3,4-DAP | 737±70† | 124±25 |
| XE-991+3,4-DAP | 319±118 | 72±27 |
| Hexamethonium+XE-991+3,4-DAP | 177±67 | |
| Reserpine+XE-991+3,4-DAP | 49±22† | |
| Methoctramine+XE-991+3,4-DAP | 176±51 | |
| Chromanol+3,4-DAP | 114±12 | |
| Retigabine+3,4-DAP | 115±34† | 71±50 |
| Reserpine+retigabine+3,4-DAP | 14±13† | |
| ICA-27243+3,4-DAP | 72±21 | |
| Reserpine+ICA-27243+3,4-DAP | 31±9† | |
Salivation does not occur in anesthetized rats, unless stimulated, as here by the 3,4-DAP-induced activation of the autonomic nervous system. Significant differences between the WKY and SHR control groups (*), between corresponding control and experimental groups (†) and between corresponding groups pre-treated with XE-991/retigabine/ICA-27243 alone and reserpine/hexamethonium/methoctramine+XE-991/retigabine/ICA-27243 (none detected) were detected as indicated.
*,†
P < 0.05.